Effects of Short-term Intensive Statin Therapy on Lipid Levels

Effects of Short-term Intensive Statin Therapy on Lipid Levels in Patients With Ischemic Stroke or Large Artery Atherosclerosis: A Prospective Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07344610

Enrollment

800

Registered

2026-01-15

Start date

2026-01-08

Completion date

2026-12-30

Last updated

2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Brief summary

Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.

Interventions

DRUGstatin

Atorvastatin 40-80mg/day, Rosuvastatin 20mg/day

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age ≥ 18 years; * Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI; or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%); * Intensive statin therapy (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20 mg/day) initiated within 24 hours of admission, with a planned continuous application for at least one week; * Signed informed consent form.

Exclusion criteria

* Use of statin therapy within 1 week prior to admission; * Receiving other lipid-lowering treatments; * Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \<1 year; * Pregnant or lactating women; * Participation in other drug clinical trials within 3 months; * Other conditions deemed unsuitable by the investigator.

Design outcomes

Primary

Measure	Time frame
Absolute reduction in Low-Density Lipoprotein Cholesterol	7±1 days

Secondary

Measure	Time frame
Absolute and relative reductions in other lipid parameters (Total Cholesterol, Triglyceride, High-Density Lipoprotein Cholesterol, Lipoprotein a)	7±1 days
Changes in high-sensitivity C-reactive protein	7±1 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026